Related Experiment Video

Updated: Sep 21, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K

Republication: Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and

Danielle Boller1, Kathrin T Doepfner1, Angela DE Laurentiis1

  • 1Division of Clinical Chemistry and Biochemistry, and University Children's Hospital Zurich, Zurich, Switzerland.

Anticancer Research
|May 31, 2022
PubMed
Abstract

Insights

Class II phosphoinositide 3-kinase C2β (PI3KC2β) is overexpressed in several cancers. Inhibiting PI3KC2β reduces cancer cell proliferation and survival, suggesting it as a potential therapeutic target.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Eight human catalytic phosphoinositide 3-kinase (PI3K) isoforms exist, divided into three classes.
  • Class I PI3Ks are well-researched in cancer, but class II PI3Ks functions remain largely unknown.

Purpose of the Study:

  • To investigate the expression pattern and functions of the class II PI3KC2β isoform in various cancer types.
  • To determine the potential of PI3KC2β as a novel therapeutic target in malignancies.

Main Methods:

  • Analysis of PI3KC2β expression in tumor samples and cell lines.
  • Utilizing pharmacological inhibitors and RNA interference to study PI3KC2β function.
  • Assessing the impact of PI3KC2β inhibition on cancer cell proliferation, apoptosis, and chemosensitivity.

Main Results:

  • PI3KC2β overexpression was observed in acute myeloid leukemia (AML), glioblastoma multiforme (GBM), medulloblastoma (MB), neuroblastoma (NB), and small cell lung cancer (SCLC).
  • Inhibition of PI3KC2β impaired cancer cell proliferation, induced apoptosis, and sensitized cells to chemotherapy.
  • PI3KC2β plays a role in the proliferation and survival of AML, brain tumors, and neuroendocrine tumors.

Conclusions:

  • PI3KC2β is implicated in the proliferation and survival of specific cancer types, including AML, brain tumors, and neuroendocrine tumors.
  • These findings highlight PI3KC2β as a potential novel therapeutic target for these malignancies.
Keywords:
PI3KC2βacute leukemiabrain tumourscell proliferationmigrationneuroendocrine tumourspharmacological inhibition

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K